Crohnʼs disease and liver abscess due to Pediococcus sp.

Bernabeu, J.; Leo, E; Trigo, Claudio; Herrera, José Manuel Palma; Sousa, J.M.; Márquez, José Luis

doi:10.1002/ibd.21622

Cited by 12 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike liver abscesses observed in other diseases, infection is often mono‐microbial, caused by milleri Streptococcus, Fusobacterium nucleatum, Bacteroides fragilis or Staphylococcus aureus. The mechanism can be a direct extension of intra‐abdominal abscesses via portal pyaemia or secondary to an increase in intestinal mucosa permeability . Treatment consists of antibiotic therapy guided by culture results, ideally with a guided puncture and drainage in case of large abscesses.…”

Section: Other Hepatic Manifestations Than Psc Affecting Ibd Patientsmentioning

confidence: 99%

Hepatic manifestations of inflammatory bowel diseases

Restellini

Chazouillères

Frossard

2016

Liver International

View full text Add to dashboard Cite

Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural course of the disease. The prevalence of liver dysfunction rises from 3% to 50% accordingly to definitions used in different studies. Fatty liver is considered as the most common hepatobiliary complication in inflammatory bowel diseases while primary sclerosing cholangitis is the most specific one. Less frequently, inflammatory bowel diseases-associated hepatobiliary disorders include: autoimmune hepatitis/ primary sclerosing cholangitis overlap syndrome, IgG4-associated cholangiopathy, primary biliary cholangitis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis and liver abscess. The spectrum of these manifestations varies according to the type of inflammatory bowel diseases. Treatments of inflammatory bowel diseases may cause liver toxicity, although incidence of serious complications remains low. However, early diagnosis of drug-induced liver injury is of major importance as it affects future clinical management. When facing abnormal liver tests, clinicians should undertake a full diagnostic work-up in order to determine whether the hepatic abnormalities are related to the inflammatory bowel diseases or not.Management of hepatic manifestations in inflammatory bowel diseases usually involves both hepatologists and gastroenterologists because of the complexity of some situations. K E Y W O R D Sdrug-induced liver injury, hepatotoxicity, inflammatory bowel disease, liver disease, primary sclerosing cholangitis

show abstract

Section: Other Hepatic Manifestations Than Psc Affecting Ibd Patientsmentioning

confidence: 99%

Hepatic manifestations of inflammatory bowel diseases

Restellini

Chazouillères

Frossard

2016

Liver International

View full text Add to dashboard Cite

show abstract

“…Among the extraintestinal complications of IBD, PLA is a rare but severe disorder. Previous case reports, mostly from Western countries, described that PLA was observed more frequently in patients with Crohn's disease . In a review article in 2004, only seven (11.7%) cases of PLA occurred in patients with ulcerative colitis among the 60 cases of PLA in patients with IBD .…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies have demonstrated an increased incidence of portal bacteraemia in patients with IBD . However, PLA remains a rare extraintestinal manifestation of IBD and only sporadic reports of PLA in IBD cases have been described in literature . The incidence rate of PLA in patients with IBD has never been assessed.…”

mentioning

confidence: 99%

Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study

Lin

et al. 2015

Liver International

View full text Add to dashboard Cite

show abstract

“…Pediococcus species Bernabeu et al (2011) report an association between Pediococcus species and liver abscess. The patient had a long history of Crohn´s disease and this is a very rare complication, according to the literature search of the authors.…”

Section: 18mentioning

confidence: 94%

Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2011 update)

2011

EFSA Journal

View full text Add to dashboard Cite

EFSA is requested to assess the safety of a broad range of biological agents (including microorganisms and viruses) in the context of notifications for market authorisation as sources of food and feed additives, enzymes and plant protection products. The qualified presumption of safety (QPS) assessment was developed by EFSA for its own use to provide a generic risk assessment approach applicable across EFSA's scientific Panels, for biological agents notified for intentional use in the whole food chain. The safety of unambiguously defined biological agents at the highest taxonomic unit that is appropriate for the purpose for which an application is intended and the completeness of the body of knowledge are assessed. Identified safety concerns for a taxonomic unit are where sensible reflected as ‘qualifications’ when a recommendation for the QPS list is given. The list of QPS recommended biological agents is reviewed and updated annually. Therefore, the only valid list is the one in the most recent scientific opinion. The 2011 update reviews microorganisms previously assessed including bacteria, yeasts, filamentous fungi and viruses used for plant protection purposes and confirms the previous recommendations. The anamorph yeast form Phaffia rhodozyma of Xanthophyllomyces dendrorhous was included on the QPS list and to the qualification for yeasts ‘absence of resistance to antimycotics used for medical treatment of yeast infections’, the sentence was added that ‘in the case of Saccharomyces cerevisiae this qualification applies for yeast strains able to grow above 37 °C’. The body of knowledge of filamentous fungi and enterococci was updated and their ineligibility for the QPS list confirmed.

show abstract

Crohnʼs disease and liver abscess due to Pediococcus sp.

Cited by 12 publications

References 10 publications

Hepatic manifestations of inflammatory bowel diseases

Hepatic manifestations of inflammatory bowel diseases

Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study

Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2011 update)

Contact Info

Product

Resources

About